Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
Duke Survey Clinical trials: Research Conflicts of Interest Violate ethical Guidelines_UPI Sun, 27 Oct 2002 A major Duke University survey of 108 U.S. medical schools reveals that medical institutions fail utterly to meet international standards aimed at ensuring the integrity of clinical research and the safety of the subjects. Conflicts…
Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Sun, 11 Dec 2005 Two major cases of medical research fraud on each side of the Atlantic involve evidence of fraud and data tampering by pharmaceutical company giants. Both cases provide insight into the way in…
NHLBI director Dr. Lenfant is Retiring Thu, 3 Jul 2003 The retirement of Dr. Claude Lenfant, director of the National Heart, Lung, and Blood Institute (NHLBI) was announced today. Not mentioned in the press release is the heated controversy surrounding two clinical trials sponsored by the NHLBI, conducted by the…
European perspective: Bird Flu–BBC Panoarama / German skeptics / Rumsfeld Tamiflu stock $5 to $25 million Sat, 5 Nov 2005 As the media continues its senstional coverage of the “Bird Flu pandemic”, healthy skeptics are examining the evidence. Two European examinations–The BBC Panorama will air a program, Lessons from Vietnam,…
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
FDA Standards – Good Enough for Government Work? Fri, 23 Sep 2005 An essay in The New England Journal of Medicine, by Jerry Avorn, M.D., professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, chalolenges FDA’s “minimalist” drug…
Research dispute prompts patient-trials debate_Seattle Times Mon, 19 May 2003 Newhouse News Service reports that the continuing dispute about the ethics and design of a multi-site lung ventilation experiment sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and conducted by the ARDSNetwork on 861 critically ill patients with…
Practice Guidelines: Can We Trustthe Evidence in Evidence-Based Medicine? Sun, 25 Sep 2005 “Research and Clinical Practice Guidelines: Can We Trust the Evidence in Evidence-Based Medicine?” is an article by Dr. John Abramson* (Harvard) and Dr. Barbara Starfeld (Distinguished Professor, Johns Hopkins), published in the Journal of the American Board…
Lilly's aggressive marketing of Xigris does indeed epitomize the worst ofthis industry's mission.
"Academic officials acknowledged in the published guidelines that Lilly gave more than 90 percent of $861,000 in grants for the campaign and medical recommendations. About a fifth of the 46 guidelines writers acknowledged previously taking money from Eli Lilly for speaking, consulting or research."
"The drugs most commonly used to soothe agitation and aggression in people with Alzheimer’s disease are no more effective than placebos for most patients, and put them at risk of serious side effects, including confusion, sleepiness and Parkinson’s disease-like symptoms, researchers are reporting
today."
